Does the media favor GEHC or MDLN?

In the previous week, GE HealthCare Technologies had 50 more articles in the media than Medline. MarketBeat recorded 59 mentions for GE HealthCare Technologies and 9 mentions for Medline. GE HealthCare Technologies' average media sentiment score of 0.88 beat Medline's score of 0.86 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 29 Very Positive mention(s) 6 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medline 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MDLN or PHG?

Medline presently has a consensus price target of $50.54, indicating a potential upside of 24.88%. Given Medline's stronger consensus rating and higher possible upside, research analysts plainly believe Medline is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medline 1 Sell rating(s) 5 Hold rating(s) 22 Buy rating(s) 1 Strong Buy rating(s) 2.79 Koninklijke Philips 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media favor MDLN or PHG?

In the previous week, Koninklijke Philips had 5 more articles in the media than Medline. MarketBeat recorded 14 mentions for Koninklijke Philips and 9 mentions for Medline. Medline's average media sentiment score of 0.86 beat Koninklijke Philips' score of 0.56 indicating that Medline is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Koninklijke Philips 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings & valuation, ZBH or MDLN?

Medline has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.28 $705.20M $3.85 25.17 Medline $28.43B 1.87 $1.16B $0.32 126.47

Does the media prefer ZBH or MDLN?

In the previous week, Zimmer Biomet had 8 more articles in the media than Medline. MarketBeat recorded 17 mentions for Zimmer Biomet and 9 mentions for Medline. Zimmer Biomet's average media sentiment score of 0.90 beat Medline's score of 0.86 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medline 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MDLN or SOLV?

Solventum has lower revenue, but higher earnings than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.87 $1.16B $0.32 126.47 Solventum $8.33B 1.83 $1.56B $8.16 10.78

Is MDLN or SOLV more profitable?

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Solventum 17.33% 23.51% 7.63%

Does the media favor MDLN or SOLV?

In the previous week, Solventum had 2 more articles in the media than Medline. MarketBeat recorded 11 mentions for Solventum and 9 mentions for Medline. Solventum's average media sentiment score of 0.87 beat Medline's score of 0.86 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, MDLN or SNN?

Medline has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.87 $1.16B $0.32 126.47 Smith & Nephew SNATS $6.16B 2.21 $625M N/A N/A

Is MDLN or SNN more profitable?

Company Net Margins Return on Equity Return on Assets Medline N/A N/A N/A Smith & Nephew SNATS N/A N/A N/A

Does the media prefer MDLN or SNN?

In the previous week, Medline had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for Medline and 5 mentions for Smith & Nephew SNATS. Medline's average media sentiment score of 0.86 beat Smith & Nephew SNATS's score of 0.54 indicating that Medline is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medline (MDLN) Competitors

$40.47 +1.19 (+3.03%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$40.10 -0.37 (-0.91%)

As of 08/3/2026 07:50 PM Eastern

Compare

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

Should you buy Medline stock or one of its competitors? MarketBeat compares Medline with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medline include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN).

How does Medline compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, GE HealthCare Technologies had 50 more articles in the media than Medline. MarketBeat recorded 59 mentions for GE HealthCare Technologies and 9 mentions for Medline. GE HealthCare Technologies' average media sentiment score of 0.88 beat Medline's score of 0.86 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	29 Very Positive mention(s)	6 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medline	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has a net margin of 9.33% compared to Medline's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.12% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.33%	20.12%	5.74%
Medline	N/A	N/A	N/A

GE HealthCare Technologies currently has a consensus target price of $77.73, indicating a potential upside of 11.47%. Medline has a consensus target price of $50.54, indicating a potential upside of 24.88%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 0.8% of Medline shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GE HealthCare Technologies has higher earnings, but lower revenue than Medline. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$21.27B	1.48	$2.08B	$4.36	15.99
Medline	$28.43B	1.87	$1.16B	$0.32	126.47

Summary

GE HealthCare Technologies and Medline tied by winning 8 of the 16 factors compared between the two stocks.

How does Medline compare to Koninklijke Philips?

Medline (NASDAQ:MDLN) and Koninklijke Philips (NYSE:PHG) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Koninklijke Philips had 5 more articles in the media than Medline. MarketBeat recorded 14 mentions for Koninklijke Philips and 9 mentions for Medline. Medline's average media sentiment score of 0.86 beat Koninklijke Philips' score of 0.56 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Medline presently has a consensus price target of $50.54, indicating a potential upside of 24.88%. Given Medline's stronger consensus rating and higher possible upside, research analysts plainly believe Medline is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Koninklijke Philips	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Koninklijke Philips has a net margin of 6.30% compared to Medline's net margin of 0.00%. Koninklijke Philips' return on equity of 14.38% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Koninklijke Philips	6.30%	14.38%	5.96%

Medline has higher revenue and earnings than Koninklijke Philips. Koninklijke Philips is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.87	$1.16B	$0.32	126.47
Koninklijke Philips	$20.17B	1.28	$1.01B	$1.36	19.28

Summary

Medline beats Koninklijke Philips on 10 of the 16 factors compared between the two stocks.

How does Medline compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Zimmer Biomet had 8 more articles in the media than Medline. MarketBeat recorded 17 mentions for Zimmer Biomet and 9 mentions for Medline. Zimmer Biomet's average media sentiment score of 0.90 beat Medline's score of 0.86 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medline	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 0.8% of Medline shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Medline has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.28	$705.20M	$3.85	25.17
Medline	$28.43B	1.87	$1.16B	$0.32	126.47

Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Medline	N/A	N/A	N/A

Zimmer Biomet currently has a consensus target price of $102.00, indicating a potential upside of 5.24%. Medline has a consensus target price of $50.54, indicating a potential upside of 24.88%. Given Medline's stronger consensus rating and higher possible upside, analysts plainly believe Medline is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.24
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Zimmer Biomet beats Medline on 9 of the 15 factors compared between the two stocks.

How does Medline compare to Solventum?

Medline (NASDAQ:MDLN) and Solventum (NYSE:SOLV) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Solventum had 2 more articles in the media than Medline. MarketBeat recorded 11 mentions for Solventum and 9 mentions for Medline. Solventum's average media sentiment score of 0.87 beat Medline's score of 0.86 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has lower revenue, but higher earnings than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.87	$1.16B	$0.32	126.47
Solventum	$8.33B	1.83	$1.56B	$8.16	10.78

Medline currently has a consensus price target of $50.54, indicating a potential upside of 24.88%. Solventum has a consensus price target of $86.00, indicating a potential downside of 2.22%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Solventum	17.33%	23.51%	7.63%

Summary

Medline and Solventum tied by winning 7 of the 14 factors compared between the two stocks.

How does Medline compare to Smith & Nephew SNATS?

Medline (NASDAQ:MDLN) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Medline has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.87	$1.16B	$0.32	126.47
Smith & Nephew SNATS	$6.16B	2.21	$625M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Smith & Nephew SNATS	N/A	N/A	N/A

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.8% of Medline shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Medline presently has a consensus target price of $50.54, indicating a potential upside of 24.88%. Smith & Nephew SNATS has a consensus target price of $30.93, indicating a potential downside of 4.05%. Given Medline's stronger consensus rating and higher possible upside, equities analysts plainly believe Medline is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Medline had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for Medline and 5 mentions for Smith & Nephew SNATS. Medline's average media sentiment score of 0.86 beat Smith & Nephew SNATS's score of 0.54 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medline beats Smith & Nephew SNATS on 8 of the 11 factors compared between the two stocks.

Get Medline News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDLN vs. The Competition

Export

Metric	Medline	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.60B	$5.67B	$6.86B	$12.44B
Dividend Yield	N/A	1.78%	2.60%	10.03%
P/E Ratio	126.47	23.62	280.72	24.99
Price / Sales	1.87	58.66	588.10	90.57
Price / Cash	23.16	32.53	28.64	34.82
Price / Book	2.76	6.50	11.02	6.21
Net Income	$1.16B	$151.15M	$3.48B	$347.49M
7 Day Performance	-0.10%	3.01%	0.80%	1.29%
1 Month Performance	-6.30%	-1.18%	-4.17%	-3.59%
1 Year Performance	N/A	3.40%	61.47%	18.38%

Medline Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDLN Medline	4.5889 of 5 stars	$40.47 +3.0%	$50.54 +24.9%	N/A	$51.60B	$28.43B	126.47	45,000
GEHC GE HealthCare Technologies	4.7026 of 5 stars	$68.46 -4.8%	$77.05 +12.5%	-0.2%	$31.25B	$20.63B	16.44	54,000	Earnings Report Analyst Forecast Gap Up
PHG Koninklijke Philips	2.7445 of 5 stars	$26.40 +1.1%	N/A	-0.9%	$25.98B	$20.17B	19.48	65,340	Analyst Forecast Gap Down
ZBH Zimmer Biomet	2.9939 of 5 stars	$94.21 -3.0%	$102.00 +8.3%	+6.9%	$18.24B	$8.41B	24.48	17,000	Positive News Upcoming Earnings
SOLV Solventum	2.9669 of 5 stars	$87.20 -1.5%	$86.00 -1.4%	+22.6%	$15.12B	$8.33B	10.70	20,000	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDLN) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medline (MDLN) Competitors

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Medline compare to GE HealthCare Technologies?

Summary

How does Medline compare to Koninklijke Philips?

Summary

How does Medline compare to Zimmer Biomet?

Summary

How does Medline compare to Solventum?

Summary

How does Medline compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDLN vs. The Competition

Medline Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medline (MDLN) Competitors

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

How does Medline compare to GE HealthCare Technologies?

Does the media favor GEHC or MDLN?

Is GEHC or MDLN more profitable?

Do analysts prefer GEHC or MDLN?

Do insiders and institutionals believe in GEHC or MDLN?

Which has stronger earnings & valuation, GEHC or MDLN?

Summary

How does Medline compare to Koninklijke Philips?

Does the media favor MDLN or PHG?

Do analysts prefer MDLN or PHG?

Do insiders & institutionals believe in MDLN or PHG?

Is MDLN or PHG more profitable?

Which has better valuation & earnings, MDLN or PHG?

Summary

How does Medline compare to Zimmer Biomet?

Does the media prefer ZBH or MDLN?

Do insiders and institutionals hold more shares of ZBH or MDLN?

Which has higher earnings & valuation, ZBH or MDLN?

Is ZBH or MDLN more profitable?

Do analysts recommend ZBH or MDLN?

Summary

How does Medline compare to Solventum?

Does the media favor MDLN or SOLV?

Which has stronger valuation and earnings, MDLN or SOLV?

Do analysts prefer MDLN or SOLV?

Is MDLN or SOLV more profitable?

Summary

How does Medline compare to Smith & Nephew SNATS?

Which has better valuation & earnings, MDLN or SNN?

Is MDLN or SNN more profitable?

Do institutionals and insiders believe in MDLN or SNN?

Do analysts prefer MDLN or SNN?

Does the media prefer MDLN or SNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDLN vs. The Competition

Medline Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools